[1]魏 伟.炎症免疫反应软调节[J].中国药理学通报,2016,(03):297-303.[doi:10.3969/j.issn.1001-1978.2016.03.001]
 WEI Wei.Soft regulation of inflammatory immune responses[J].Chinese Pharmacological Bulletin,2016,(03):297-303.[doi:10.3969/j.issn.1001-1978.2016.03.001]
点击复制

炎症免疫反应软调节()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2016年03期
页码:
297-303
栏目:
讲座与综述
出版日期:
2016-03-15

文章信息/Info

Title:
Soft regulation of inflammatory immune responses
文章编号:
1001-1978(2016)03-0297-07
作者:
魏 伟
安徽医科大学临床药理研究所,抗炎免疫药物教育部重点实验室, 抗炎免疫药物安徽省协同创新中心,安徽 合肥 230032
Author(s):
WEI Wei
Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Hefei 230032, China
关键词:
炎症免疫反应 炎症免疫反应软调节 免疫细胞 细胞因子 信号转导 新药发现
Keywords:
inflammatory immune responses(IIR) soft regulation of inflammatory immune responses(SRIIR) immune cells cytokines signal transduction discovery of new drugs
分类号:
R-05; R392.11; R392.12; R364.5; R971.1
DOI:
10.3969/j.issn.1001-1978.2016.03.001
文献标志码:
A
摘要:
炎症反应和免疫反应在整体、组织、细胞和分子等各层次密不可分。该文提出炎症免疫反应(inflammatory immune responses, IIR)是机体炎症免疫相关细胞依据内外环境变化所表现出的适度或异常的系统反应; 简述了参与IIR的炎症免疫细胞(巨噬细胞、树突细胞、T细胞、B细胞等及其亚型)、非炎症免疫细胞(如胶质细胞、内皮细胞、上皮细胞、成纤维细胞、滑膜细胞、肝细胞等)及细胞因子/受体信号转导的研究进展,指出了目前临床上使用的影响IIR药物存在的问题,提出炎症免疫反应软调节(soft regulation of inflammatory immune responses,SRIIR)是研发治疗IIR相关疾病创新药物的新方向。
Abstract:
Inflammation reaction and immune response are inseparable in the levels of system, tissue, cell and molecule. Inflammatory immune responses(IIR)is proposed in this paper, which is defined a moderate or abnormal system responses of inflammatory immune related cells in responding to the internal and external environment changes of body. It is described briefly that the research progresses of inflammatory immune cells(e.g., macrophages, dendritic cells, T cells and B cells, etc.)and non-inflammatory immune cells(e.g., glial cells, endothelial cells, epithelial cells, fibroblasts, synovial cells and liver cells, etc.), and cytokines/receptor signal transduction involved in IIR. Moreover, the existing problems about regulating IIR drugs clinically are summarized. It is firstly put forward that soft regulation of inflammatory immune responses(SRIIR)is a new direction of discovery and development of new drugs for the treatment of IIR related diseases.

参考文献/References:

[1] 魏 伟,李晓辉,张洪泉,等.抗炎免疫药理学[M]. 北京:人民卫生出版社,2005.
[1] Wei W, Li X H, Zhang H Q, et al. anti-inflammatory immune pharmacology[M]. Beijing: People's Medical Publishing house, 2005.
[2] Goronzy J,Weyand C. Developments in the scienti c understanding of rheumatoid arthritis[J]. Arthritis Res Ther, 2009,11:1-14.
[3] Arend W P. Physiology of cytokine pathways in rheumatoid arthritis[J]. Arthritis Care Res, 2001,45:101-6.
[4] Luan B, Yoon Y S, Le Lay J, et al. CREB pathway links PGE2 signaling with macrophage polarization[J]. Proc Natl Acad Sci USA, 2015,112(51):15642-7.
[5] Chow K V, Lew A M, Sutherland R M,et al. Monocyte-derived dendritic cells promote Th polarization, whereas conventional dendritic cellspromote Th proliferation[J]. J Immunol, 2016,196(2):624-36.
[6] Lobo P I, Schlegel K H, Bajwa A, et al. Natural IgM switches the function of lipopolysaccharide-activated murine bone marrow-derived dendriticcells to a regulatory dendritic cell that suppresses innate inflammation[J]. J Immunol,2015,195(11):5215-6.
[7] Yan D, Farache J, Mathis D, Benoist C. Imbalanced signal transduction in regulatory T cells expressing the transcription factor FoxP3[J]. Proc Natl Acad Sci USA, 2015, 112(48):14942-7.
[8] Patel D D, Kuchroo V K. Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions[J]. Immunity, 2015,43(6):1040-51.
[9] Gaublomme J T, Yosef N, Lee Y, et al. Single-cell genomics unveils critical regulators of Th17 cell pathogenicity[J]. Cell, 2015,163(6):1400-12.
[10] 张玲玲,魏 伟. 调节性B细胞在炎症免疫相关疾病的调控作用及机制[J].中国药理学通报,2012, 28(7):889-93.
[10] Zhang L L, Wei W. Regulation and mechanisms of regulatory B cell in inflammation and immune related diseases[J]. Chin Pharmacol Bull, 2012, 28(7):889-93.
[11] 刘亢亢,汪庆童,黄 蓓,等.调节性B细胞的功能及在类风湿关节炎免疫反应中的作用[J]. 免疫学杂志, 2013,9:800-3.
[11] Liu K K,Wang Q T, Huang B, et al. Effect of regulatory B cell in immune response of rheumatoid arthritis[J]. J Immunol, 2013,9:800-3.
[12] Rosser E C, Mauri C. Regulatory B cells: origin, phenotype, and function[J]. Immunity, 2015,42(4):607-12.
[13] Ransohoff R M, Melissa M A. Innate immunity in the central nervous system[J]. J Clin Invest, 2012,122(4):1164-71.
[14] Burzynski L C, Humphry M, Bennett M R, et al. Interleukin-1α activity in necrotic endothelial cells Is controlled by caspase-1 cleavage of interleukin-1 receptor-2: implications for allograft rejection[J]. J Biol Chem, 2015,290(41):25188-96.
[15] Denney L, Byrne A J, Shea T J, et al. Pulmonary epithelial cell-derived cytokine TGF-β1 is a critical cofactor for enhanced innate lymphoidcell function[J]. Immunity, 2015,43(5):945-58..
[16] Takahashi H, Sakakura K, Kawabata-Iwakawa R, et al. Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma[J]. Cancer Immunol Immunother, 2015,64(11):1407-17.
[17] Jia X Y, Chang Y, Sun X J, et al. Total glucosides of paeony inhibit the proliferation of fibroblast-like synoviocytes through the regulation of G proteins in rats with collagen-induced arthritis[J]. Int Immunopharmacol, 2014,18(1):1-6.
[18] Yang L, Inokuchi S, Roh Y S, et al. Transforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1[J]. Gastroenterology, 2013,144(5):1042-54.
[19] Iwata Y, Furuichi K, Hashimoto S, et al. Pro-inflammatory/Th1 gene expression shift in high glucose stimulated mesangial cells and tubular epithelial cells[J]. Biochem Biophys Res Commun, 2014,443(3):969-74.
[20] Artis D, Spits H. The biology of innate lymphoid cells[J]. Nature,2015,517:293-301.
[21] Braumüller H, Wieder T. T-helper-1-cell cytokines drive cancer into senescence[J]. Nature,2013,494:361-5.
[22] Zhu W, London N R, Gibson C C, et al. Interleukin receptor activates a MYD88-ARNO-ARF6 cascade to disrupt vascular stability[J]. Nature,2012, 492: 252-5.
[23] Rathert P, Roth M,Neumann T, et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition[J]. Nature,2015, 525:543-7.
[24] O'Shea J J, Jones R G. Autoimmunity: Rubbing salt in the wound[J]. Nature,2013, 496:437-9.
[25] Choy E H,Panayi G S. Cytokine pathways and joint in ammation in rheumatoid arthritis[J]. N Engl J Med, 2001,344: 907-16.
[26] 王 迪, 胡姗姗,魏 伟. 血管紧张素Ⅱ及其受体与类风湿关节炎[J]. 中国药理学通报,2014,30(10):1353-6.
[26] Wang D, Hu S S, Wei W. Angiotensin Ⅱ and receptors in rheumatoid arthritis[J]. Chin Pharmacol Bull, 2014,30(10):1353-6.
[27] Rudloff I, Godsell J, Nold-Petry C A, et al. Brief report: interleukin-38 exerts antiinflammatory functions and is associated with disease activity in systemic lupus erythematosus[J]. Arthritis Rheumatol, 2015,67(12):3219-25.
[28] Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature, 2005,435:612-9.
[29] Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation[J]. Nature,2015, 517:311-20.
[30] Wang Q T, Wu Y J, Huang B, et al. Etanercept attenuates collagen-induced arthritis by modulating the association between BAFFR expression and the production of splenic memory B cells[J]. Pharmacol Res, 2013,68(1):38-45.
[31] Wang D, Dubois R N. Prostaglandins and cancer[J]. Gut, 2006,55(1):115-22.
[32] Chen J Y, Wu H X, Chen Y, et al. Paeoniflorin inhibits proliferation of fibroblast-like synoviocytes through suppressing G-protein-coupledreceptor kinase 2[J]. Planta Medica, 2012, 78(7):665-71.
[33] Luan B, Yoon Y S, Le Lay J, et al. CREB pathway links PGE2 signaling with macrophage polarization[J]. Proc Natl Acad Sci USA, 2015,112(51):15642-7.
[34] Rodriguez-Rodriguez L, Jover-Jover J A, Fontsere O, et al.Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis[J]. Scand J Rheumatol, 2013,42(6):433-6.
[35] Kim S C, Solomon D H, Liu J, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs[J]. Am J Med, 2015,128(5):539.e7-17.
[36] Katchamart W, Trudeau J, Phumethum V, et al. Efficacy and toxicity of methotrexate(MTX)monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis[J]. Ann Rheum Dis, 2009,68(7):1105-12.
[37] Curtis J R, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide[J]. Ann Rheum Dis, 2010,69(1):43-7.
[38] Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review[J]. Semin Arthritis Rheum, 2014,43(5):613-26.
[39] Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis[J]. N Engl J Med, 2012, 367(6):495-507.
[40] Cohen S B, Koenig A, Wang L, et al. Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase Ⅱand Ⅲ[J]. Clin Exp Rheumatol, 2016,34(1):32-6.
[41] Yun H, Xie F, Delzell E, et al. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare[J]. Arthritis Rheumatol, 2016,68(1):56-66.
[42] Notley C A, Ehrenstein M R. The yin and yang of regulatory T cells and inflammation in RA[J]. Nat Rev Rheumatol, 2010,6(10):572-7.
[43] Kim W B, Marinas J E, Qiang J, et al. Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study[J]. J Am Acad Dermatol, 2015,73(2):237-41.
[44] Ramiro S, Gaujoux-Viala C, Nam J L, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis[J]. Ann Rheum Dis, 2014,73(3):529-35.
[45] Davies R, Southwood T R, Kearsley-Fleet L, et al. Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept: Results from the british society for paediatric and adolescent rheumatology etanercept cohort study[J]. Arthritis Rheumatol, 2015,67(9):2487-94.
[46] Chiu Y M, Lang H C, Lin H Y, et al. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan[J]. Int J Rheum Dis, 2014,17(Suppl 3):9-19.
[47] Burmester G R, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis(SUMMACTA study)[J]. Ann Rheum Dis, 2014,73(1):69-74.
[48] Merrill J T, Ginzler E M, Wallace D J, et al. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus[J]. Arthritis Rheum, 2012,64(10):3364-73.
[49] Leonard A N, Love B L, Norris L B, et al. Screening for viral hepatitis prior to rituximab chemotherapy[J]. Ann Hematol, 2016,95(1):27-33.
[50] 李 影,陈镜宇,张玲玲,等. 肿瘤坏死因子相关因子参与炎症免疫调节的研究进展[J]. 中国药理学通报, 2015,31(9):1206-11.
[50] Li Y, Chen J Y, Zhang L L, et al. Research advance of tumor necrosis factor receptor-associated factors in inflammatory immune regulation[J]. Chin Pharmacol Bull, 2015,31(9):1206-11.

相似文献/References:

[1]张玲玲,魏 伟.治疗自身免疫病药物研究进展[J].中国药理学通报,2019,(02):149.[doi:10.3969/j.issn.1001-1978.2019.02.001]
 ZHANG Ling-ling,WEI Wei.Advance in drug treatment of autoimmune diseases[J].Chinese Pharmacological Bulletin,2019,(03):149.[doi:10.3969/j.issn.1001-1978.2019.02.001]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金重点项目资助(No 81330081)
作者简介:魏 伟(1960-),男,博士,教授,研究方向:抗炎免疫药理学和临床药理学,E-mail:wwei@ahmu.edu.cn
更新日期/Last Update: 2016-03-15